Compare Stocks

Date Range: 

 ObsEvaCalithera BiosciencesSavaraMatinas BioPharmaLantern Pharma
SymbolNASDAQ:OBSVNASDAQ:CALANASDAQ:SVRANYSEAMERICAN:MTNBNASDAQ:LTRN
Price Information
Current Price$3.08$2.05$1.28$1.16$12.29
50-Day Moving Average$2.75$2.16$1.35$1.11$13.17
52-Week Low$1.86$1.78$1.00$0.67$10.29
52-Week High$5.55$6.18$3.58$2.22$24.84
MarketRank™
Overall Score1.62.22.21.82.0
Analysis Score3.33.33.53.43.5
Community Score4.34.84.44.85.0
Dividend Score0.00.00.00.00.0
Ownership Score0.02.53.30.01.7
Earnings & Valuation Score0.60.60.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$14.33$3.67$4.67$3.33$29.00
% Upside from Price Target365.37% upside78.86% upside264.58% upside187.36% upside135.96% upside
Trade Information
Market Cap$177.26 million$151.93 million$145.73 million$249.10 million$137.45 million
Beta0.781.691.232.641.37
Average Volume3,057,4791,126,2382,105,9372,687,695130,243
Sales & Book Value
Annual Revenue$20,000.00$22.25 million$260,000.00$160,000.00N/A
Price / Sales8,863.166.83560.481,556.87N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.15 per share$1.45 per share$1.19 per share$0.30 per share$1.88 per share
Price / Book20.531.411.083.87N/A
Profitability
Net Income$-82,970,000.00$-90,140,000.00$-49,620,000.00$-22,450,000.00$-5,910,000.00
EPS($1.67)($1.31)N/A($0.12)($1.37)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-269.94%-79.58%-38.18%-34.47%-18.49%
Return on Assets (ROA)-94.67%-66.42%-30.08%-29.90%-18.03%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.61%N/A0.15%N/AN/A
Current Ratio3.64%7.53%32.56%16.97%30.56%
Quick Ratio3.64%7.53%32.56%16.97%30.55%
Ownership Information
Institutional Ownership Percentage31.71%63.29%66.92%17.92%12.05%
Insider Ownership PercentageN/A11.60%4.77%7.80%30.30%
Miscellaneous
Employees4593N/A2013
Shares Outstanding57.55 million74.11 million113.85 million214.74 million11.18 million
Next Earnings Date11/4/2021 (Estimated)11/4/2021 (Estimated)11/4/2021 (Estimated)11/5/2021 (Estimated)11/4/2021 (Estimated)
OptionableNot OptionableOptionableOptionableNot OptionableNot Optionable
SourceHeadline
Lantern Pharma IncLantern Pharma Inc
money.usnews.com - September 14 at 10:28 PM
Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During SeptemberLantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September
finance.yahoo.com - September 7 at 6:25 PM
Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing InitiativesLantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives
finance.yahoo.com - September 2 at 4:53 PM
Lantern Pharma: FDA Grants Additional Orphan Drug Designation For LP-184 - Quick FactsLantern Pharma: FDA Grants Additional Orphan Drug Designation For LP-184 - Quick Facts
nasdaq.com - August 30 at 4:11 PM
FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant GliomasFDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas
finance.yahoo.com - August 30 at 9:17 AM
Preclinical Data Of Brain Tumor Candidate Fails To Lift Lantern Pharma StockPreclinical Data Of Brain Tumor Candidate Fails To Lift Lantern Pharma Stock
finance.yahoo.com - August 25 at 7:39 PM
Lantern Pharma Inc.Lantern Pharma Inc.
barrons.com - August 19 at 4:24 PM
Lantern Pharma Reports Positive Data From Preclinical Study With LP-184 In GlioblastomaLantern Pharma Reports Positive Data From Preclinical Study With LP-184 In Glioblastoma
markets.businessinsider.com - August 19 at 4:24 PM
Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research CollaborationLantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration
finance.yahoo.com - August 19 at 11:24 AM
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic CancerLantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer
finance.yahoo.com - August 16 at 9:33 AM
Lantern Pharma Gets FDA Orphan Designation for LP-184 in Pancreatic Cancer >LTRNLantern Pharma Gets FDA Orphan Designation for LP-184 in Pancreatic Cancer >LTRN
marketwatch.com - August 11 at 12:57 PM
Lantern Pharmas LP-184 Gets Orphan Drug Designation In Treatment Of Pancreatic CancerLantern Pharma's LP-184 Gets Orphan Drug Designation In Treatment Of Pancreatic Cancer
nasdaq.com - August 11 at 12:57 PM
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic CancerFDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
finance.yahoo.com - August 11 at 12:57 PM
How Many Lantern Pharma Inc. (NASDAQ:LTRN) Shares Do Institutions Own?How Many Lantern Pharma Inc. (NASDAQ:LTRN) Shares Do Institutions Own?
finance.yahoo.com - August 9 at 1:11 PM
LTRN: 2Q:21 ResultsLTRN: 2Q:21 Results
finance.yahoo.com - August 5 at 12:27 PM
Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational HighlightsLantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights
finance.yahoo.com - July 29 at 7:23 PM
Lantern Pharma Reacquires Rights To Commercialization Of IrofulvenLantern Pharma Reacquires Rights To Commercialization Of Irofulven
cmlviz.com - July 27 at 12:13 PM
Lantern Pharma Reacquires Rights To Phase 2 Clinical Trial In Metastatic Prostate CancerLantern Pharma Reacquires Rights To Phase 2 Clinical Trial In Metastatic Prostate Cancer
nasdaq.com - July 27 at 12:13 PM
Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/SLantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
finance.yahoo.com - July 27 at 12:13 PM
Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of IrofulvenAllarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven
wallstreet-online.de - July 26 at 3:26 AM
Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ETLantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET
finance.yahoo.com - July 22 at 6:09 PM
“The Buzz” Show: Lantern Pharma (NASDAQ: LTRN) Positive Cancer Collaboration Data“The Buzz” Show: Lantern Pharma (NASDAQ: LTRN) Positive Cancer Collaboration Data
financialbuzz.com - July 20 at 6:05 PM
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall StreetThe Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
msn.com - July 20 at 1:05 PM
Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal ModelsLantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models
finance.yahoo.com - July 20 at 1:05 PM
Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
finance.yahoo.com - July 20 at 8:04 AM
DateCompanyBrokerageAction
9/15/2021ObsEvaHC Wainwright
Reiterated Rating
9/14/2021Matinas BioPharmaHC Wainwright
Reiterated Rating
8/9/2021ObsEvaHC Wainwright
Reiterated Rating
8/9/2021Calithera BiosciencesHC Wainwright
Reiterated Rating
7/30/2021Lantern PharmaColliers Securities
Reiterated Rating
7/28/2021ObsEvaWedbush
Reiterated Rating
7/21/2021Lantern PharmaColliers Securities
Reiterated Rating
7/2/2021ObsEvaWedbush
Reiterated Rating
5/14/2021SavaraHC Wainwright
Reiterated Rating
5/11/2021Matinas BioPharmaPiper Sandler
Downgrade
5/10/2021Calithera BiosciencesHC Wainwright
Reiterated Rating
3/30/2021Matinas BioPharmaHC Wainwright
Reiterated Rating
3/16/2021SavaraPiper Sandler
Initiated Coverage
3/15/2021SavaraOppenheimer
Initiated Coverage
2/15/2021Matinas BioPharmaAegis
Reiterated Rating
1/29/2021Matinas BioPharmaMaxim Group
Reiterated Rating
1/12/2021ObsEvaWedbush
Reiterated Rating
1/12/2021ObsEvaSVB Leerink
Boost Price Target
1/5/2021Calithera BiosciencesSmith Barney Citigroup
Lower Price Target
1/5/2021Calithera BiosciencesHC Wainwright
Lower Price Target
1/5/2021Calithera BiosciencesSVB Leerink
Downgrade
1/4/2021ObsEvaHC Wainwright
Lower Price Target
1/4/2021Matinas BioPharmaPiper Sandler
Boost Price Target
12/15/2020SavaraHC Wainwright
Lower Price Target
11/23/2020SavaraEvercore ISI
Initiated Coverage
11/9/2020ObsEvaJPMorgan Chase & Co.
Downgrade
11/6/2020Matinas BioPharmaMaxim Group
Initiated Coverage
10/5/2020ObsEvaHC Wainwright
Lower Price Target
8/18/2020Lantern PharmaThinkEquity
Reiterated Rating
8/18/2020Lantern PharmaColliers Securities
Reiterated Rating
8/14/2020ObsEvaWedbush
Reiterated Rating
8/13/2020Matinas BioPharmaAegis
Boost Price Target
8/11/2020Calithera BiosciencesSVB Leerink
Lower Price Target
8/11/2020Matinas BioPharmaHC Wainwright
Reiterated Rating
8/10/2020Lantern PharmaThinkEquity
Initiated Coverage
7/28/2020Lantern PharmaColliers Securities
Initiated Coverage
7/7/2020ObsEvaSVB Leerink
Lower Price Target
7/7/2020ObsEvaJPMorgan Chase & Co.
Downgrade
7/6/2020ObsEvaBMO Capital Markets
Downgrade
7/1/2020ObsEvaHC Wainwright
Reiterated Rating
7/1/2020ObsEvaWedbush
Reiterated Rating
6/5/2020ObsEvaHC Wainwright
Reiterated Rating
6/2/2020Calithera BiosciencesWilliam Blair
Reiterated Rating
6/2/2020Matinas BioPharmaAegis
Reiterated Rating
5/23/2020Matinas BioPharmaMaxim Group
Initiated Coverage
5/13/2020Matinas BioPharmaMaxim Group
Reiterated Rating
5/11/2020Calithera BiosciencesCitigroup
Boost Price Target
5/8/2020Calithera BiosciencesHC Wainwright
Reiterated Rating
5/5/2020ObsEvaWedbush
Reiterated Rating
4/1/2020Matinas BioPharmaMaxim Group
Initiated Coverage
3/27/2020Calithera BiosciencesCitigroup
Lower Price Target
3/27/2020Calithera BiosciencesJefferies Financial Group
Initiated Coverage
3/23/2020ObsEvaWedbush
Reiterated Rating
3/23/2020ObsEvaHC Wainwright
Lower Price Target
3/17/2020SavaraHC Wainwright
Reiterated Rating
3/11/2020Calithera BiosciencesSVB Leerink
Reiterated Rating
3/6/2020Matinas BioPharmaMaxim Group
Reiterated Rating
3/5/2020ObsEvaWedbush
Boost Price Target
1/26/2020Matinas BioPharmaPiper Sandler
Initiated Coverage
1/23/2020Matinas BioPharmaSunTrust Banks
Initiated Coverage
1/21/2020ObsEvaWedbush
Reiterated Rating
1/21/2020ObsEvaHC Wainwright
Reiterated Rating
1/9/2020Matinas BioPharmaAegis
Initiated Coverage
12/20/2019SavaraHC Wainwright
Reiterated Rating
12/20/2019Matinas BioPharmaHC Wainwright
Reiterated Rating
12/19/2019ObsEvaHC Wainwright
Reiterated Rating
12/10/2019ObsEvaRoyal Bank of Canada
Boost Price Target
12/2/2019ObsEvaHC Wainwright
Reiterated Rating
11/27/2019Calithera BiosciencesHC Wainwright
Initiated Coverage
11/19/2019Calithera BiosciencesHC Wainwright
Initiated Coverage
10/3/2019SavaraLADENBURG THALM/SH SH
Reiterated Rating
9/26/2019Matinas BioPharmaMaxim Group
Reiterated Rating
8/14/2019Matinas BioPharmaHC Wainwright
Reiterated Rating
8/12/2019SavaraEvercore ISI
Set Price Target
8/9/2019Calithera BiosciencesCitigroup
Set Price Target
6/26/2019Matinas BioPharmaHC Wainwright
Reiterated Rating
6/26/2019Matinas BioPharmaHC Wainwright
Initiated Coverage
6/21/2019Calithera BiosciencesWilliam Blair
Reiterated Rating
6/13/2019SavaraCanaccord Genuity
Lower Price Target
6/13/2019SavaraHC Wainwright
Lower Price Target
6/13/2019SavaraLADENBURG THALM/SH SH
Downgrade
6/13/2019SavaraJMP Securities
Downgrade
5/30/2019Calithera BiosciencesCitigroup
Reiterated Rating
5/17/2019Matinas BioPharmaBTIG Research
Initiated Coverage
5/16/2019Matinas BioPharmaMaxim Group
Reiterated Rating
5/14/2019SavaraRoth Capital
Set Price Target
5/10/2019SavaraLADENBURG THALM/SH SH
Reiterated Rating
4/1/2019SavaraLADENBURG THALM/SH SH
Reiterated Rating
3/25/2019SavaraCanaccord Genuity
Set Price Target
2/11/2019Matinas BioPharmaRoth Capital
Reiterated Rating
12/20/2018SavaraHC Wainwright
Reiterated Rating
11/8/2018SavaraHC Wainwright
Reiterated Rating
(Data available from 9/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.